Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 784

Sort by

Sort Order Select

Journal Articles

Targeting cereblon in AML

Steven Grant

Blood (2021) 137 (5): 584–586.

https://doi.org/10.1182/blood.2020009827

Published: 2021

Journal Articles

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Blood (2021) 137 (5): 661–677.

https://doi.org/10.1182/blood.2020008676

Published: 2021

Includes: Supplemental data

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Coexistence of a Huge Venous Thromboembolism and Bleeding Tendency in Cytokine Release Syndrome during CAR-T Therapy

Haiyan Liu, MD, Ye Yang, PhD, Hongming Huang, MD

Blood (2019) 134 (Supplement_1): 5590.

https://doi.org/10.1182/blood-2019-129389

Published: 2019

Journal Articles

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Pallavi Mehta, MD DM, Neha Yadav, BDS , MBA, Mohan Bhaarat, Sumeet Prakash Mirgh, MBBS, MDDM, Vishvdeep Khushoo, MBBS, MDDM, Shinto Francis Thekuddan, MBBS, MDDM, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5572.

https://doi.org/10.1182/blood-2019-131674

Published: 2019

Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Blood (2019) 134 (Supplement_1): 5642.

https://doi.org/10.1182/blood-2019-122776

Published: 2019

Journal Articles

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

Saurabh Mishra, MD DNB, Ashok K Vaid, MDDM, Nitin Sood, MDFRCPath,MRCP, Manorama Bhargava, Bhuvan Chugh, DNB, Roshan Dixit, MD, Amrita Ramaswami, MDDM, Devender Sharma, MD

Blood (2019) 134 (Supplement_1): 5559.

https://doi.org/10.1182/blood-2019-125752

Published: 2019

Journal Articles

Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study

Herve Ghesquieres, MD PhD, Youenn Drouet, PhD, Sarah Huet, PharmD PhD, Guillaume Cartron, Marie-Helene Delfau, MD PhD, Fritz Offner, MD, Pauline Brice, Luc Xerri, MD PhD, Reda Bouabdallah, Gilles A. Salles, MD PhD

Blood (2019) 134 (Supplement_1): 2780.

https://doi.org/10.1182/blood-2019-130357

Published: 2019

Journal Articles

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, MD, Amer M. Zeidan, MBBS, MHS, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 2547.

https://doi.org/10.1182/blood-2019-124291

Published: 2019

Journal Articles

CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML)

Antonia Lopez-Girona, Gang Lu, Emily Rychak, Derek Mendy, Chin-Chun Lu, Irit Rappley, Celia Fontanillo, Brian E. Cathers, Thomas O. Daniel, Joshua Hansen

Blood (2019) 134 (Supplement_1): 2703.

https://doi.org/10.1182/blood-2019-127892

Published: 2019

Journal Articles

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Liqing Jin, MD, Nathan Mbong, Stanley W.K. Ng, PhD, Jean C.Y. Wang, MD, Mark D. Minden, MD PhD, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, MD, John E. Dick, PhD

Blood (2019) 134 (Supplement_1): 3940.

https://doi.org/10.1182/blood-2019-128450

Published: 2019

Journal Articles

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Manish R. Patel, MD, Guillermo Garcia-Manero, MD, Ronald Paquette, MD, Shira Dinner, MD, William B. Donnellan, MD, Michael R. Grunwald, MD, Maria D Ribadeneira, PhD, Patricia Schroeder, Julie Brevard, Lindsey Wilson, Jennifer Sweeney, Patrick Kelly, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 3907.

https://doi.org/10.1182/blood-2019-124741

Published: 2019

Journal Articles

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Pau Abrisqueta, MD PhD, Juan-Manuel Sancho, MD PhD, Raul Cordoba, MD PhD, Daniel O. Persky, MD, Charalambos Andreadis, MD MSCE, Scott F. Huntington, MD MPH, Cecilia Carpio, MD, Daniel Morillo Giles, MD, Xin Wei, PhD, Ying Fei Li, PhD, Marlene Zuraek, MD, Michael R. Burgess, Kristen Hege, Alejandro Martín, MD PhD

Blood (2019) 134 (Supplement_1): 4089.

https://doi.org/10.1182/blood-2019-125310

Published: 2019

Journal Articles

Use of Routine Bloodwork on General Internal Medicine Inpatients: A Retrospective Cohort Study

William K Silverstein, MD, Adina S. Weinerman, MD MHSc, FRCPC, Rick Wang, MMath, Lisa K. Hicks, MD MSc, R. Sacha Bhatia, MD MBA, FRCPC, Wendy Levinson, MD OC, Fahad Razak, MD MSc, FRCPC, Amol Verma, MD MPhil, FRCPC

Blood (2019) 134 (Supplement_1): 56.

https://doi.org/10.1182/blood-2019-124219

Published: 2019

Journal Articles

Identification of ST3GAL6-AS1 Interactive Protein in Multiple Myeloma

Ying Shen, MD, Fangmei Li, PhD, Dong Wu, MD, Yue Peng, Wanhong Zhao, MD, Yun Yang, MD, Jianli Wang, MD, Ju Bai, PhD, Yan Xu, Aili He

Blood (2019) 134 (Supplement_1): 4365.

https://doi.org/10.1182/blood-2019-125210

Published: 2019

Journal Articles

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

Blood (2019) 134 (Supplement_1): 3119.

https://doi.org/10.1182/blood-2019-124298

Published: 2019

Journal Articles

MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy

Brandon Imber, MD MA, M. Lia Palomba, MD, Carl DeSelm, MD PhD, Connie Lee Batlevi, MD PhD, Parastoo B. Dahi, MD, Sergio A. Giralt, MD, Ariela Noy, MD, Jae H. Park, MD, Craig S. Sauter, MD, Michael Scordo, MD, Gunjan L. Shah, MDMS, Michel Sadelain, MD PhD, Miguel-Angel Perales, MD, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 3238.

https://doi.org/10.1182/blood-2019-131449

Published: 2019

Journal Articles

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 670.

https://doi.org/10.1182/blood-2019-127119

Published: 2019

Journal Articles

Frequent Impaired Overall Neurocognitive and Executive Function in Children Ages 1-12 Years of Age with Sickle Cell Anemia in Uganda

Amelia Boehme, PhD MSPH, Paul Bangirana, MS, PhD, Annet Birabwa, MS, Deogratias Munube, MD, Ezekiel Mupere, MMed, MS, PhD, Robert Opoka, MMED, Philip Kasirye, MMED, Philip LaRussa, MD, Nancy S. Green, MD, Richard Idro, MMED, PhD

Blood (2019) 134 (Supplement_1): 1015.

https://doi.org/10.1182/blood-2019-131509

Published: 2019

Journal Articles

Defining Germline Predisposition to Dnmt3a -Mutant Clonal Hematopoiesis (CH)

Logan Sari Schwartz, BS, Kristina Mujica, Rebecca Bell, BA, Matthew Loberg, BA, Jennifer Trowbridge, PhD

Blood (2019) 134 (Supplement_1): 1198.

https://doi.org/10.1182/blood-2019-124530

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting cereblon in AML

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Coexistence of a Huge Venous Thromboembolism and Bleeding Tendency in Cytokine Release Syndrome during CAR-T Therapy

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML)

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Use of Routine Bloodwork on General Internal Medicine Inpatients: A Retrospective Cohort Study

Identification of ST3GAL6-AS1 Interactive Protein in Multiple Myeloma

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

Frequent Impaired Overall Neurocognitive and Executive Function in Children Ages 1-12 Years of Age with Sickle Cell Anemia in Uganda

Defining Germline Predisposition to Dnmt3a -Mutant Clonal Hematopoiesis (CH)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only